Purpose Diethylenetriamine-pentaacetic acid (DTPA)-coupled minigastrins are unsuitable for therapeutic application with the available β-emitting radiometals due to low complex stability. Low tumour-to-kidney ratio of the known radiopharmaceuticals is further limiting their potency. We used macrocyclic chelators for coupling to increase complex stability, modified the peptide sequence to enhance radiolytic stability and studied tumour-to-kidney ratio and metabolic stability using 111 In-labelled derivatives. Methods Gastrin derivatives with decreasing numbers of glutamic acids were synthesised using In-labelled radiopeptides showed receptor-specific internalisation. Serum mean-life times varied between 2.0 and 72.6 h, positively correlating with the number of Glu residues. All 111 In-labelled macrocyclic chelator conjugates showed higher tumour-to-kidney ratios after 24 h (0.37-0.99) compared to 111 In-DTPA-minigastrin 0 (0.05). Tumour wash out between 4 and 24 h was low. Imaging studies confirmed receptor-specific blocking of the tumour uptake. Conclusions Reducing the number of glutamates increased tumour-to-kidney ratio but resulted in lower metabolic stability. The properties of the macrocyclic chelator-bearing derivatives make them potentially suitable for clinical purposes.
I-
CCK as radioligand. Internalisation was evaluated in AR4-2J cells. Enzymatic stability was determined by incubating the 111 In-labelled peptides in human serum. Biodistribution was performed in AR4-2J-bearing Lewis rats.
Results IC 50 values of the nat In-metallated gastrin derivatives vary between 1.2 and 4.8 nmol/L for all methioninecontaining derivatives. Replacement of methionine by norleucine, isoleucine, methionine-sulfoxide and methioninesulfone resulted in significant decrease of receptor affinity (IC 50 between 9.9 and 1,195 nmol/L). All cholecystokinin receptor affinities were >100 nmol/L. All 111 In-labelled radiopeptides showed receptor-specific internalisation. Serum mean-life times varied between 2.0 and 72.6 h, positively correlating with the number of Glu residues. All 111 In-labelled macrocyclic chelator conjugates showed higher tumour-to-kidney ratios after 24 h (0.37-0.99) compared to Introduction peptides with identical carboxytermini [2] . Gastrin binds to the cholecystokinin (CCK) receptors, which are found physiologically on parietal and enterochromaffin-like cells.
The two receptors of the gastrin-CCK family that consists of the CCK and the gastrin receptor are Gprotein-coupled receptors [3] . Gastrin shows low affinity to the CCK receptor, which is mainly expressed in the gall bladder, gastric smooth muscle, pancreas and peripheral nerve system. Conversely, gastrin has high affinity to the gastrin receptor, which is mainly expressed in the gastric mucosa, endocrine pancreas and brain [4, 5] . Gastrin receptors are also overexpressed in medullary thyroid cancer [6] , small cell lung cancer, stromal ovarian cancer, gastrointestinal adenocarcinoma and in neuroendocrine tumours [7] [8] [9] [10] . Therefore, the gastrin receptor appears to be a promising target for diagnostic and therapeutic application of radiolabelled gastrin analogues [11] [12] [13] [14] .
Non-sulfated CCK analogues or, alternatively, minigastrin analogues, have recently been introduced for imaging and treatment of medullary thyroid carcinoma patients [15] [16] [17] [18] [19] [20] [21] [22] . Derivatives for labelling with 111 In or 90 Y employed the acyclic chelator diethylenetriamine-pentaacetic acid (DTPA); however, the [ 90 Y-DTPA] monoamide complexes are not stable enough for targeted radionuclide therapy [23] . To increase the complex stability, a DTPAGlu chelator was employed [21] ; however, the low tumour-to-kidney ratio restricted its therapeutic use [18, 19, 22] . Alternatively, macrocyclic chelators like 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 1-(1-carboxy-3-carboxypropyl)-1,4,7,10-tetraazacyclododecane-4,7,10-triacetic acid (DOTAGA) provide higher stability compared to acyclic chelators [24] , whereas DOTAGA provides faster labelling kinetics [25, 26] .
Thus, we coupled minigastrins with macrocyclic chelators to increase their complex stability. We also modified the peptide sequence to increase the important tumour-tokidney ratio and radiolytic stability.
Materials and methods

Synthesis of chelator-peptide conjugates
All chemicals were commercially available and used without further purification. DOTAGA(tBu) 4 and DOTA (tBu) 3 were synthesised as previously described [24, 27] . DTPA(tBu) 3 was obtained commercially (Mallinckrodt Medical, USA). All peptides were assembled on Rink amide MBHA resin (0.6 mmol/g; NovaBiochem, Switzerland) using solid phase peptide synthesis on a semiautomatic peptide synthesiser (Rink Combichem Technologies, Switzerland). Three equivalents of Fmoc-protected amino acids (NovaBiochem, Switzerland) based on resin loading with 3.3 equivalents of N-hydroxy-benzotriazole, 3.3 equivalents of N,N′-diisopropylcarbodiimide and five equivalents of N-ethyldiisopropylamine were used for coupling (reaction time: 45 min). Fmoc was removed with 20% piperidine/N,Ndimethylformamide. The tBu-protected chelator was attached using two equivalents of the prochelator with two equivalents of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-phosphate. Deprotection and cleavage from resin was performed by adding a solution of 91% of trifluoroacetic acid (TFA), 3% H 2 O, 5% thioanisole and 1% of triisopropyl-silane. The crude product was precipitated using a 1:1 mixture of diisopropylether/petrolether. Purification was done by preparative high-performance liquid chromatography (HPLC) using Uptisphere UP5ODB/25M column (Laubscher Labs, Switzerland), Bischof 2250 HPLC pumps and λ-1010 UV-detector (Metrohm AG, Switzerland). The products were lyophilised and characterised by ESI-MS (Waters ZMD; Waters-Micromass, USA, with HP1100 Quaternary LC pump; Hewlett Packard, USA) or MALDI-MS (Voyager sSTR equipped with Nd/YAG laser (355 nm); Applied BioSystems, USA). Purity was checked by HPLC (Macherey-Nagel Nucleosil 120-3 C 18 reversed phase column on 1050 HPLC system; Hewlett Packard, Germany, Berthold LB506 Cl γ-detector, Germany) with the gradient: eluent A: 0.1% TFA in water, eluent B: acetonitrile; 0 min 95% A, 30 min 55% A, 32 min 0% A, 34 min 0% A; flow: 0.75 mL/min; λ: 214 nm.
Radiolabelling
Radiolabelling was performed as previously described [28] . Three hundred microlitres of a 0.4 mol/L sodium acetate buffer pH 5 was added to an aliquot of 5 μg of the corresponding peptide-chelator conjugate, followed by 37 MBq 111 InCl 3 (Mallinckrodt, The Netherlands) and heated for 30 min at 95°C. For internalisation and serum stability studies, five equivalents of nat InCl 3 were added and heated again for 30 min to 95°C, and excess nat InCl 3 was separated by solid phase extraction using a SepPak C 18 cartridge (Waters, Switzerland). The radiopeptide was immobilised on the cartridge; excess of nat InCl 3 was rinsed off with water. Finally, the product was eluted with methanol, evaporated to dryness and reconstituted in water. Quality control after radiolabelling was performed using the HPLC system described above and the following gradient: eluent A: 0.1% TFA in water, eluent B: acetonitrile; 0 min 95% A, 5 min 95% A, 10 min 0% A, 15 min 0% A; flow: 0.75 mL/min.
Binding affinity studies on CCK-or gastrin-expressing tissues Binding affinities were evaluated as previously described [29] in surgically extracted human tumour tissues selected from previous experiments to express either cholecystokinin and gastrin receptors [5, 7] . Increasing amounts of nat Inlabelled minigastrin derivatives were added to the 125 Ilabelled D-Tyr-Gly-Asp-Tyr(SO 3 H)-Nle-Gly-Trp-Nle-AspPhe-amide ( 125 I-CCK) containing incubation medium to generate competitive inhibition curves. Tissue slides were exposed to Biomax MR films (Kodak) for 1-7 days. Autoradiograms were quantified using tissue standards for iodinated compounds (Amersham, UK) [30] .
Enzymatic stability in human serum
After labelling with 111 In/ nat InCl 3 , 40 pmol of each compound was added to 2 mL fresh human blood serum and incubated at 37°C and 5% CO 2 ; 150 μL of this solution was removed at different time intervals and added to 150 μL of ethanol. The precipitate was separated by centrifugation (10 min, 1,850×g, 4°C). The supernatant was analysed by HPLC as described above.
Cell culture and in vitro internalisation assay on AR4-2J cells
Gastrin receptor-positive AR4-2J rat pancreatic tumour cells [31] were kept in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, amino acids and vitamins (Amimed, BioConcept, Switzerland). The internalisation experiments were performed as previously described [32, 33] . One million AR4-2J cells were washed with DMEM and allowed to rest for 1 h at 37°C in 1.2 mL of medium. An amount of 0.25 pmol (2.8 kBq) of the 111 In/ nat In-labelled chelator-peptide conjugates was added to a final concentration of 0.167 nmol/L, and cells were incubated at 37°C in 5% CO 2 . To study non-receptorspecific uptake, >10
4 -fold excess of unlabelled DOTAminigastrin 11 (3 nmol/well) was added. The internalisation was stopped after different incubation times (30 min, 1, 2 and 4 h) by removal of the medium. Cells were washed twice with phosphate-buffered saline (pH 7.2, 4°C) and then twice with glycine buffer (5 min, 0.05 mol/L glycine, pH 2.8, 4°C) to discriminate between cell surface-bound (acid releasable) and internalised radioligand. Cells were then incubated with 1 mol/L NaOH (10 min, 37°C) to release them from the plate. All fractions were collected in triplicates, and quantitative γ-counting was done using a COBRA II, D 5003 γ-system well counter (Canberra Packard, USA).
Biodistribution and SPECT/CT imaging in AR4-2J-bearing Lewis rats
All animal experiments were approved and performed according to the national regulations for animal treatment (Bundesamt für Veterinärwesen, approval no. 789). Ten million AR4-2J rat pancreatic tumour cells were subcutaneously implanted in the right posterior limb of 6-week-old Lewis rats (Harlan, The Netherlands). Two weeks after inoculation of the tumour cells, 0.1 nmol (1.1 MBq) of the corresponding 111 In-labelled chelator-peptide conjugate (dissolved in 200 μL of saline supplemented with 0.1% human serum albumin) was injected intravenously under inhalation anaesthesia (3 vol.% isoflurane with 0.6 L O 2 / min). To determine non-specific tumour uptake, 100 μg (71.3 nmol) unlabelled DOTA-minigastrin 11 was added to the injection solution. The rats (in groups of three to five animals, 160-180 g body weight and 6-15 mm tumour diameter) were sacrificed 4 or 24 h post-injection, respectively, under anaesthesia.
Organs of interest were collected, rinsed of excess blood, plotted dry and weighed. The radioactivity of the different samples was quantified on a γ-counter.
Four hours after injection of the radioligand, the sacrificed animals were placed on a SPECT/CT-camera (Symbia T2, Siemens, Germany) for the acquisition of images. Iteratively reconstructed SPECT images (four subsets, eight iterations) were combined with three-dimensional reconstructed images from the spiral CT (1.25 mm slices, 1.2 mm reconstruction increment, 130 kV, 48 mA s).
Statistical methods
Discrete variables are expressed as counts (percentage) and continuous variables as mean ± standard deviation, unless stated otherwise. A first-order decay model was used to calculate serum mean-life time values. Receptor-specific internalisation was calculated as difference between nonblocked and blocked uptake and expressed as percentage of applied activity. Organ uptakes were calculated and expressed as percentage of injected activity per gram tissue (%IA/g). A linear regression model was employed to examine the association of internalisation rates, binding affinities, tumour uptake and kidney uptake. p values of <0.05 were considered to be statistically significant.
Results
Synthesis of chelator-peptide conjugates
The following compounds were synthesised: DOTA-minigastrin 9 (minigastrin 9: DGlu-Glu-Glu-Ala-Tyr-Gly-TrpMet-Asp-Phe-NH 2 ), DOTA-minigastrin 10 (minigastrin 10: DGlu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 ), DOTA-minigastrin 11 (minigastrin 11: DGlu-Ala-Tyr-Gly-Trp-Met-AspPhe-NH 2 ), DOTAGA-minigastrin 11 and DTPA-minigastrin 11 ( Fig. 1) . In addition, DOTA-minigastrin 11-based compounds, with the amino acid methionine replaced by isoleucine (Ile), norleucine (Nle), methionine-sulfoxide (Met (O)) or methionine-sulfone (Met(O 2 )) were synthesised. All conjugates showed purities >95% as confirmed by HPLC; identities were confirmed by mass spectroscopy. Both synthesised DTPA-conjugates showed shorter HPLC retention times than the DOTA-conjugates (Table 1 
In vitro internalisation into AR4-2J cells
The internalised fractions, expressed as percent of the injected activity per 1 million cells over a 4-h period, are shown in Table 3 . The 4-h values of all compounds significantly decreased to <0.5% after addition of excess of unlabelled DOTA-minigastrin 11 (p<0.001). The surfacebound radioligand did not exceed 2% of the added radioactivity after 4 h.
Biodistribution studies in AR4-2J-bearing Lewis rats
Organ uptakes are listed in Table 4 ; a detailed list is provided in Supplemental Table 1 Fig. 3a ), high internalisation rates (r=0.71, Fig. 3b ) and high blood serum stabilities (r=0.67, Fig. 3c ). Coinjection of excess of unlabelled DOTA-minigastrin 11 significantly reduced the uptake of [ Table 4 ). The kidney uptake was negatively correlated to the overall compound Fig. 3d ). Uptake in gastrin receptor-negative tissues, e.g. the kidneys, was not significantly influenced by excess of blocking agent (Table 4 ). The resulting tumour-tokidney ratios 24 h post-injection were in the following, in increasing order (Table 4) 
SPECT/CT imaging
The combined SPECT/CT image clearly showed the accumulation of the radiolabelled compounds in the tumour (Fig. 4) . Discussion DTPA-coupled minigastrin and CCK derivatives have previously been employed for labelling with radiometals [19, 21, 22] ; however, the acyclic structure of DTPA led to a high rate of decomplexation of the radioisotopes. This instability restricted the therapeutic use of these radiopeptides [23] . Contrary to the acyclic chelator DTPA, the macrocyclic chelators DOTA and DOTAGA offer higher kinetic inertness and thereby prevent significant decomplexation [34] .
Coupling to macrocyclic chelators resulted in minigastrin derivatives with the potential of a stable complexation of α-and β-emitting radiometals. Furthermore, decreasing the number of glutamic acid residues of the gastrin derivatives significantly increased the tumour-to-kidney ratio. These properties allow reduction of the undesired uptake of the radionuclide into non-target organs during radiopeptide therapy.
In this study, we successfully coupled both DOTA and DOTAGA to the gastrin derivatives, retaining a high binding affinity and receptor-specific internalisation capacity. The in vivo studies revealed low intestinal retention of our compounds, which indicates a low hepatobiliary excretion.
Methionine-containing radiopeptides like gastrin commonly undergo auto-oxidation to sulfoxides during synthesis and more strikingly during radiolabelling. This effect is particularly observed after labelling with α-and β-emitting radionuclides, which frequently cause oxidation of thioether-containing amino acids via radiolysis [35] . On the one hand, this process can be suppressed by the addition of radical scavengers such as gentisic acid, ascorbic acid or methionine to the labelling solution [36] . On the other hand, the occurrence of auto-oxidation can be avoided by substitution of methionine with methionine mimics like methionine-sulfone, methionine-sulfoxide, norleucine or others [37] . However, in this study, replacement of methionine resulted in a distinct loss of binding affinity to the gastrin receptor, except for the norleucine derivative. This loss was considerable after employing isoleucine, methionine-sulfone or methionine-sulfoxide, respectively. Hence, these compounds, except the norleucine derivative, are unsuitable for receptor targeting.
Our results indicate that the number of negative charges of the N-terminally bound Glu residues in the sequence of minigastrin has a positive influence on metabolic stability and on binding affinity. We also used DOTAGA, among other reasons like fast labelling kinetics [25] , to study if a chelatebased negative charge has a similar effect. The additional negative charge did also enhance the metabolic stability.
Kidney uptake of radiolabelled peptides by tubular reabsorption often restricts the maximum therapeutic dose [38] and, therefore, is the major limitation in radiopeptide therapy [39, 40] . Thus, reduction of kidney uptake is essential to improve the efficacy of radiopeptide therapy. On the one hand, coinjection of polyglutamic acid was shown to reduce the accumulation of DTPA-minigastrin 0 in the kidneys up to a factor of ten [41] ; on the other hand, previous oral communications have indicated that modification of the peptides might also be useful to reduce kidney uptake [42, 43] . In our experiments, the modification of the peptide sequence even exceeded previously reported effects. Deletion of five glutamic acid residues in the sequence of minigastrin 0 led to a reduction of kidney accumulation by more than a factor of 25. This led to a subsequent improvement of tumour-to-kidney ratio despite the lower serum stability of the compounds. The lower tumour uptake must be ascribed to the lower metabolic stability. The decreased kidney uptake can potentially be explained by the loss of the negative charges of the glutamic acids, which may be responsible for tubular reabsorption of radiolabelled peptides. This hypothesis is strengthened by recent results from Behe et al. [41] of significantly reduced kidney uptake by coinjection of polyglutamates [41, 44] . If factors other than the overall compound charge also have affected renal retention, this may be shown with new series of gastrin-based peptides having different hydrophilic spacers. Interestingly, the use of the chelator DOTAGA did not increase the kidney uptake as compared to DOTA despite the additional negative charge. Among other factors, the low tumour uptake possibly is a result of the low gastrin receptor density on the AR4-2J cells. Notably, the reduction of the peptide sequence had only minor influence on the binding affinity. The slow wash out, as demonstrated by the insignificant decrease of tumour uptake after 24 h, may allow using the minigastrin derivatives for therapeutic applications. Furthermore, good imaging capabilities of gastrin-positive tissues were achieved, as shown by the SPECT/CT images of the AR4-2J tumour-bearing Lewis rat.
Our results have implications for further research directed towards a higher tumour uptake of the radiolabelled minigastrin analogues. We have shown that higher receptor affinity, as well as higher serum stability, results in higher tumour accumulation. Therefore, in upcoming studies, both factors have to be considered in order to achieve further progress in the development of radiolabelled minigastrin analogues.
[ 111 In-DOTA]-minigastrin 11 displayed the highest tumourto-kidney ratio in the animal biodistribution studies. On the other hand, [ 111 In-DOTA]-minigastrin 9 showed the highest gastrin receptor affinity in human tissues, as well as the highest stability of the DOTA-coupled minigastrins in human blood serum. Which of the present compounds will offer the greatest benefit to the patient, however, remains elusive to the first clinical trials.
In conclusion, our modified minigastrins show improved tumour-to-kidney ratios, while the coupling with DOTA and DOTAGA provides a high radiometal complex stability. These properties make these derivates favourable for clinical studies of gastrin receptor-positive tumours. Nevertheless, further developments leading to a higher metabolic stability should improve the bioavailability of the radiopharmaceutical.
